Q3 Earnings Estimate for ZVRA Issued By HC Wainwright

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Stock analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for shares of Zevra Therapeutics in a report issued on Tuesday, March 10th. HC Wainwright analyst B. Folkes expects that the company will earn $0.08 per share for the quarter. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Zevra Therapeutics’ FY2026 earnings at $0.23 EPS, FY2027 earnings at $1.16 EPS and FY2028 earnings at $1.75 EPS.

Other equities analysts have also recently issued reports about the stock. Guggenheim set a $23.00 target price on shares of Zevra Therapeutics and gave the company a “buy” rating in a research note on Tuesday. Weiss Ratings raised shares of Zevra Therapeutics from a “sell (d+)” rating to a “hold (c+)” rating in a report on Tuesday. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

Zevra Therapeutics Stock Performance

NASDAQ ZVRA opened at $10.41 on Wednesday. The firm has a market capitalization of $586.06 million, a P/E ratio of 7.83 and a beta of 0.91. The stock has a 50-day simple moving average of $8.88 and a two-hundred day simple moving average of $9.08. The company has a debt-to-equity ratio of 0.40, a quick ratio of 8.57 and a current ratio of 5.68. Zevra Therapeutics has a fifty-two week low of $6.19 and a fifty-two week high of $13.16.

Insider Buying and Selling

In other Zevra Therapeutics news, SVP Timothy J. Sangiovanni sold 3,000 shares of the company’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $9.18, for a total value of $27,540.00. Following the completion of the sale, the senior vice president directly owned 29,590 shares in the company, valued at $271,636.20. This represents a 9.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Neil F. Mcfarlane sold 91,000 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $9.38, for a total transaction of $853,580.00. Following the completion of the sale, the chief executive officer directly owned 364,350 shares of the company’s stock, valued at $3,417,603. This represents a 19.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 114,158 shares of company stock valued at $1,062,878 over the last ninety days. 2.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Marshall Wace LLP purchased a new stake in Zevra Therapeutics in the third quarter valued at approximately $8,676,000. Rubric Capital Management LP boosted its holdings in shares of Zevra Therapeutics by 60.8% in the second quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock valued at $17,253,000 after acquiring an additional 740,584 shares during the period. Royce & Associates LP purchased a new position in shares of Zevra Therapeutics during the third quarter worth approximately $6,574,000. Adage Capital Partners GP L.L.C. increased its holdings in shares of Zevra Therapeutics by 15.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock valued at $36,720,000 after acquiring an additional 550,000 shares during the period. Finally, Nantahala Capital Management LLC increased its holdings in shares of Zevra Therapeutics by 34.0% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock valued at $18,753,000 after acquiring an additional 500,000 shares during the period. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Zevra Therapeutics

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: Miplyffa commercial momentum: FY2025 results showed 350% revenue growth to $106.5M and GAAP EPS of $1.40, driven by rapid uptake of Miplyffa in the ultra‑rare NPC market — supports near‑term revenue visibility and payer coverage gains. Article Title
• Positive Sentiment: Diagnostic partnership: GeneDx will launch a genetic testing program with Zevra to help identify patients with suspected Niemann‑Pick disease type C, which could expand the addressable patient base and support future prescriptions. Article Title
• Positive Sentiment: Regulatory optimism: Analysts and media noted upbeat Q4 results and optimism ahead of a potential EMA decision for Zevra’s NPC treatment — a positive catalyst if approval is received. Article Title
• Neutral Sentiment: Company disclosures: Full Q4/FY2025 earnings call transcript and formal press release provide the underlying details behind the strong top‑line and one‑time items; useful for modeling sustainability of earnings. Article Title
• Neutral Sentiment: Valuation discussion: Coverage pieces are debating whether current pricing reflects multi‑year gains and one‑time income — this is context for whether the rally is sustainable. Article Title
• Negative Sentiment: Analyst estimate cuts: HC Wainwright trimmed FY2026–FY2028 EPS forecasts (FY26: $0.29→$0.23; FY27: $1.34→$1.16; FY28: $2.00→$1.75), signaling lower medium‑term earnings expectations and likely contributing to the pullback. (Market commentary on analyst revisions)
• Negative Sentiment: Post‑runup profit‑taking and volatility: After the strong FY25 beat and share rally, heavy trading volume suggests some investors are locking in gains while the market digests sustainability questions and the analyst downgrades.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.